Rocket Pharmaceuticals is no longer a pure clinical-stage story, but the market is still treating it like one. Accelerated approval of KRESLADI for severe leukocyte adhesion deficiency turned the Cranbury, New Jersey operator into a commercial-stage gene-therapy company on paper, while the sale of the associated rare-pediatric-disease priority review voucher filled the treasury without a new share sale. The equity debate is whether that regulatory proof and the cash it produced buy enough time for the cardiovascular franchise to recover from last year's clinical hold, or whether the share price already embeds a low-probability Danon outcome and little else.
The voucher monetization, not product sales, produced the quarter's headline profit. Operating results stayed deeply negative even after last summer's headcount cut and the decision to delay Fanconi anemia and pyruvate kinase deficiency. Cash and investments now sit near $284 million, enough on management's plan to fund operations into early 2028. That runway is the real asset. Enterprise value after cash is a thin residual, which is the market saying the ultra-rare launch and the restarted Danon trial are options, not a franchise.
What has to resolve next is whether the modified Danon protocol stays clean as more patients are treated, and whether the first KRESLADI patients actually reach Qualified Treatment Centers later this year. A second safety event would collapse the residual enterprise value back toward a cash-liquidation debate. Clean expansion of dosing, plus even a handful of commercial infusions, would argue the platform is executable again. Does the current price pay only for cash, or for a cardiac gene-therapy platform that just survived its hardest year?